These small-cap biotechs are exploding this morning

                                                                                                                                                                                                                                                                                                                                                                                                                January 19, 2023 | [Read Online]( Good day, 360 – We apologize for the “Great Subject Line Snafu” yesterday – we are actually humans putting this newsletter together (not A.I.)...but we can assure you that won’t happen again! And as always, here are our top 3 trade ideas today – be the best prepared trader on the Street! XTRX - 80% higher after progressive kidney disease treatment yields positive results in clinical trial MBLY- Shows relative strength after Deutsche Bank initiates and announces $48 price target APGN - 40% higher after announcing positive Phase 2 Data [Boardroom Investing]( is literally chomping at the bit to announce its newest investing opportunity*– this soon-to-be unveiled startup operates in (formerly) “the private playground of hedge fund tycoons and sheiks!” So join us TODAY, January 19, 1:00pm - 1:30pm (EST) for this exclusive interview, where we’ll be hearing from the CEO on: 👉 The company’s story and vision for OWNING the industry 👉 Real results (including its “in the money” track record) 👉 How you might be able to (literally) throw your hat in the ring [Click HERE to add this event – fit for a Sheik – to your Calendar!]( Or simply CLICK BELOW at 1pm ET. XTRX - 80% higher after progressive kidney disease treatment yields positive results in clinical trial XORTX Therapeutics (XRTX) announced positive topline results from its XRX-OXY-101 clinical trial of its proprietary formulation of oral oxypurinol for the treatment of kidney disease. The stock has less than 13 million shares outstanding according to [Finviz]( and has already traded 4 million shares this morning before 8am. The $1.30 level was support in the pre-market and looks like it will be an important pivot level this morning. Above it potential resistance to the upside is $1.50, $1.65 and then the pre-market high at $1.82. Above that the next significant targets would be $2 and then $2.23 with $2.48 above that. Below $1.30, $1 would be a magnet to the downside with a gap fill at about $0.78 below that. MBLY- Shows relative strength after Deutsche Bank initiates and announces $48 price target Despite the overall market being extremely weak yesterday – with the QQQ’s closing down 1.3% for the day – MBLY had independent order flow and closed the day up 6.12%, one of very few stocks closing green yesterday. Deutsche Bank’s $48 price target may have had something to do with that price action. The price target represents almost over 40% upside from here. It is one to watch today, and over the next few days, in that if the market is strong perhaps MBLY could be headed for a breakout to all-time highs. $33 has been a major support level over recent weeks and could prove to be an important pivot point today. Above it, targets to the upside are $34, 35 and then $36. All-time highs for the recent IPO are at $37.31 with blue skies above that level. Below $33 there is potential support at $32, $31.40, $30 and then $29 below that. APGN - 50% higher after announcing positive Phase 2 Data Apexigen (APGN) announced that “Results demonstrate sotigalimab's ability to turn immunologically "cold" tumors "hot" to increase anti-tumor immune responses for increased therapeutic effect in patients with esophageal/gastro-esophageal junction and rectal cancers.” The stock has less than 21 million shares and a market cap of only $46.7million based on yesterday’s close according to [Finviz](. These types of results could be a game changer for the company. Last year it traded as high $30, with the stock in the mid 2’s in pre-market. $2.40 was a support level in pre-market and could be an important pivot point today. Above it there is potential resistance at $2.60, $2.75 and the pre-market high at $2.94. The next targets would be $3.32, $3.62 and $4.50 above that. To the downside, there is potential support at $2-$2.06, with a gap fill at $1.79. Economic Calendar (EST) 8:30am ET Initial Jobless Claims 8:30am ET Housing Starts/Permits 8:30am ET Philly Fed Mfg Index 9:00am ET Fed Speak Susan Collins 10:30am ET EIA Natural Gas Report 11:00am ET EIA Petroleum Report 1:15pm ET Fed Speak Lael Brainard 6:35pm ET Fed Speak John Williams Earnings for Today (After Market) AMTB, BANR, CNXC, CSTR, FPH, INDB, MCB, NFLX, OCFC, OZK, PPG, SIVB Top Headlines TSLA price target lowered to $300 from $340 at Piper TSLA: Gigafactory Berlin has hit 9,000 employees 3,000 vehicles per week in production Tesla is hiring 200-300 new employees every week, according to comments from Brandenburg’s Economic Minister AAPL: Apple to expand smart-home lineup, taking on Amazon and Google AAPL: JPMorgan Cuts Apple Target Price To $180 From $190 AAPL IS FACING “TOUGH SETUP” FOR UPCOMING EARNINGS JPM comments DCPH: Deciphera announces $125M common stock offering. GRRR: Gorilla Technology Group Completes Asset Acquisition of SeeQuestor FAST: Fastenal surpasses $1 billion in sales outside the United States and announces cash dividend and share repurchase activity. LUV: Southwest Airlines pilot union calls for strike authorization vote Strike authorization vote will take place beginning May 1 and will be counted at the end of that month, said SWAPA, which represents more than 10,000 pilots. NIO has recently applied for the registration of the trademark “NIO PHONE”, which is classified as a scientific instrument. GOOG: India antitrust body denies Google’s allegation it copied EU’s Android order AMZN: Amazon to wind down AmazonSmile by February 20 France hit by nationwide strikes as workers take to the streets over proposed changes to retirement rules. InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS GE: GE Price target raised to $85 from $78 at Cowen NILE AULT: Ault Alliance Declares Monthly Cash Dividend of $0.2708333 Per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock NRXP: NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101 SYBX: Synlogic Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria (PKU) PLTR: Cleveland Clinic and Palantir Technologies Partner to Improve Hospital Performance Through Virtual Command Center SRDX: Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon IDCC: InterDigital wins decision from UK Court of Appeal in Lenovo dispute EDIT: Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies RPTX: Repare Therapeutics Receives $1.5 Million (Â¥200 million) Payment from Ono Pharmaceuticals PG: Procter & Gamble raises full-year sales forecast on price hikes BLCM: Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium ZCMD: Zhongchao Inc. Launches Medication Management Assistance Mini Program to Facilitate Cancer Treatment NEW 👉 360 Wall St. Events Calendar To Your Success! 62 Calef Hwy #233 Lee, New Hampshire 03861 United States Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( *ISSUER-PAID ADVERTISEMENT: This Issuer has paid RagingBull.com, LLC (“Raging Bull”) seven thousand five hundred in cash to run advertisements enhancing public awareness of the company. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of []( or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. [RagingBull.com](, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with [RagingBull.com](, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, [RagingBull.com](, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 lee, NH 03861, United States [Publish on beehiiv](